^
    Back
    Association details:
    Biomarker:RET mutation
    Cancer:Thyroid Gland Anaplastic Carcinoma
    Drug:Retevmo (selpercatinib) (RET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Selpercatinib (RET mutation-positive) was added as a preferred treatment option.
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Thyroid Gland Medullary Carcinoma)
    New
    Title:

    FDA approves selpercatinib for RET fusion-positive medullary thyroid cancer

    Excerpt:
    the Food and Drug Administration granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy.